MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells

Lung cancer is the leading cause of cancer deaths worldwide with a 5-year survival rate of 16% among patients with all stages of the disease [1]. The majority of lung cancers are classified as non-small cell lung cancer (NSCLC), and adenocarcinoma is the most common histological subtype of NSCLC. Certain subtypes of lung adenocarcinomas are treatable by effective molecular targeted drugs. For example, tyrosine kinase inhibitors against epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are highly effective against EGFR-mutant and ALK fusion-positive lung adenocarcinomas, respectively [2].

Source: Lung Cancer - May 13, 2019 Category: Cancer & Oncology Authors: Makoto Tada, Toshiyuki Sumi, Yusuke Tanaka, Sachie Hirai, Miki Yamaguchi, Masahiro Miyajima, Toshiro Niki, Hiroki Takahashi, Atsushi Watanabe, Yuji Sakuma Source Type: research